From The Stage

President & CEO Jim Datin Talks Company Culture, Core Values, and Global Growth!

Posted by BioAgilytix / /

On this episode of Molecular Moments, BioAgilytix Chief Scientific Officer Jim McNally chats with the company’s President & CEO about the exciting new updates that are putting BioAgilytix at the forefront of biotech on a global level. From multiple acquisitions to a new investor that sees the bigger picture, Datin shares how these opportunities came to be and what major deciding factors came into play when finalizing the acquisitions. The two biotech companies acquired MicroConstants in San Diego, California and 360biolabs in Melbourne and Brisbane Australia, are leaders in bioanalysis, and both are aligned with the BioAgilytix core values: Integrity,…

Cinven Completes Majority Investment in BioAgilytix

Posted by BioAgilytix / /

Investment will Power Further Expansion of Core Business and Drive Future Growth of the Company  December 21, 2021—Durham, NC, USA and London, UK—BioAgilytix, a leading global contract research organization (CRO), today announced the completion of a majority investment in the Company by Cinven, a leading international private investment firm focused on building world-class global companies.Cinven’s investment will provide BioAgilytix with increased access to funding and resources to meet the growing demand for its high-quality bioanalytical services, driven by its strong scientific reputation and leading expertise in supporting the development and…

BioAgilytix Secures Significant New Investment from Global Investor Cinven to Fuel Continued Long-Term Growth

Posted by BioAgilytix / /

Investment Will Provide BioAgilytix with Additional Resources to Invest in Core Business and Drive GrowthNovember 17, 2021—Durham, NC, USA, Brussels, Belgium and London, UK—BioAgilytix, a leading global contract research organization (CRO), today announced an agreement to be further capitalized by Cinven, a leading international private investment firm focused on building world-class global companies. Cinven will acquire a majority stake in BioAgilytix while current majority investor Cobepa, S.A., a Brussels-based private investment firm, will remain a significant minority investor in the Company.Cobepa and GHO Capital, a leading specialist investor in global healthcare, acquired…

BioAgilytix Closes Acquisition of Australia-based 360biolabs®

Posted by BioAgilytix / /

Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stagesDurham, NC, October 14, 2021 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that, following Australian Foreign Investment Review Board (“FIRB”) approval, it officially closed the purchase of 360biolabs®. The acquisition of the company, now known as 360biolabs, a BioAgilytix…

BioAgilytix Announces New Partnership With CTI

Posted by BioAgilytix / /

Alliance to strengthen both companies’ ability to provide a seamless, full-service bioanalytical client experience across the full spectrum of lifecycle developmentDurham, NC, October 4, 2021 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that it signed a formal, worldwide partnership agreement with global contract research organization Clinical Trial and Consulting Services (CTI). The partnership enables both BioAgilytix and CTI to provide their customers with mutually complementary services, further streamlining the customer experience and expediting…